![](https://www.benzinga.com/events/small-cap/wp-content/themes/small-cap/images/icons8-equity-security-100.png)
Numinus Wellness
Numinus Wellness (TSX-V: NUMI) empowers people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus Wellness model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice, and building the foundation for a healthier society.
![](https://www.benzinga.com/events/small-cap/wp-content/themes/small-cap/images/icons8-administrator-male-100.png)
Chairman & CEO
Numinus Wellness
Payton is the Co-founder, Chair & Chief Executive Officer of Numinus, a company that empowers people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. He has deep business leadership experience, particularly in the finance sector, and is a recognized innovator and visionary in mental health care.
At Numinus, he guides teams leading strategy, innovation, research and clinic network expansion, and supports the marketing and capital markets functions. He is responsible for raising over $70 million for Numinus in the past year, and is quoted widely in media such as CTV, Forbes and the New York Times. In addition, he brings more than 15 years working in finance, investment and retail banking with some of Canada’s leading independent investment firms, including Jordan Capital Markets, Canaccord Financial and Mackie Research Capital.
In these and other roles, he has raised more than $100 million for a variety of small cap companies.